{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:10:23Z","timestamp":1768410623727,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100020437","name":"Beijing Association for Science and Technology","doi-asserted-by":"crossref","award":["BYESS2022170"],"award-info":[{"award-number":["BYESS2022170"]}],"id":[{"id":"10.13039\/501100020437","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100015850","name":"Digestive Medical Coordinated Development Center of Beijing Hospitals Authority","doi-asserted-by":"publisher","award":["ZYLX202108"],"award-info":[{"award-number":["ZYLX202108"]}],"id":[{"id":"10.13039\/501100015850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10072-023-06853-2","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T11:02:15Z","timestamp":1684234935000},"page":"3647-3657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment of a comprehensive diagnostic model for neuromyelitis optica spectrum disorders based on the analysis of laboratory indicators and clinical data"],"prefix":"10.1007","volume":"44","author":[{"given":"Wencan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaowei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanghui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoge","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-5784","authenticated-orcid":false,"given":"Guojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"6853_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2174\/1381612827666210329101335","volume":"28","author":"Y Du","year":"2022","unstructured":"Du Y, Li K, Liu W, Song R, Luo M, He J et al (2022) Recent advances in neuromyelitis optica spectrum disorder: pathogenesis, mechanisms and potential treatments. Curr Pharm Des 28:272\u2013279","journal-title":"Curr Pharm Des"},{"key":"6853_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11926-021-01000-2","volume":"23","author":"RA Cruz","year":"2021","unstructured":"Cruz RA, Chaudhary S, Guevara M, Meltzer E (2021) Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist. Curr Rheumatol Rep 23:33","journal-title":"Curr Rheumatol Rep"},{"key":"6853_CR3","doi-asserted-by":"publisher","first-page":"103227","DOI":"10.1016\/j.msard.2021.103227","volume":"56","author":"S Shahmohammadi","year":"2021","unstructured":"Shahmohammadi S, Doosti R, Shahmohammadi A, Azimi A, Sahraian MA, Fattahi MR et al (2021) Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: a systematic review. Mult Scler Relat Disord 56:103227","journal-title":"Mult Scler Relat Disord"},{"key":"6853_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","volume":"19","author":"S Huda","year":"2019","unstructured":"Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A (2019) Neuromyelitis optica spectrum disorders. Clin Med (Lond) 19:169\u2013176","journal-title":"Clin Med (Lond)"},{"key":"6853_CR5","doi-asserted-by":"publisher","first-page":"e978","DOI":"10.1212\/NXI.0000000000000978","volume":"8","author":"R Marignier","year":"2021","unstructured":"Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D et al (2021) Disability outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 8:e978","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"6853_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"key":"6853_CR7","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","volume":"9","author":"N Borisow","year":"2018","unstructured":"Borisow N, Mori M, Kuwabara S, Scheel M, Paul F (2018) Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 9:888","journal-title":"Front Neurol"},{"key":"6853_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15:134","journal-title":"J Neuroinflammation"},{"key":"6853_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1055\/s-0039-3399505","volume":"39","author":"S Prasad","year":"2019","unstructured":"Prasad S, Chen J (2019) What you need to know about AQP4, MOG, and NMOSD. Semin Neurol 39:718\u2013731","journal-title":"Semin Neurol"},{"key":"6853_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.neurad.2019.06.001","volume":"46","author":"M Den\u00e8ve","year":"2019","unstructured":"Den\u00e8ve M, Biotti D, Patsoura S, Ferrier M, Meluchova Z, Mahieu L et al (2019) MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol 46:312\u2013318","journal-title":"J Neuroradiol"},{"key":"6853_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","volume":"32","author":"K Fujihara","year":"2019","unstructured":"Fujihara K (2019) Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 32:385\u2013394","journal-title":"Curr Opin Neurol"},{"key":"6853_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","volume":"31","author":"KB Holroyd","year":"2020","unstructured":"Holroyd KB, Manzano GS, Levy M (2020) Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol 31:462\u2013468","journal-title":"Curr Opin Ophthalmol"},{"key":"6853_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20:60\u201367","journal-title":"Lancet Neurol"},{"key":"6853_CR14","doi-asserted-by":"publisher","first-page":"102843","DOI":"10.1016\/j.msard.2021.102843","volume":"50","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chang H, Zhang X, Yin L (2021) Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis. Mult Scler Relat Disord 50:102843","journal-title":"Mult Scler Relat Disord"},{"key":"6853_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J (2021) Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation 18:208","journal-title":"J Neuroinflammation"},{"key":"6853_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG (2021) Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol 17:759\u2013773","journal-title":"Nat Rev Neurol"},{"key":"6853_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR et al (2019) Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol 15:671\u2013683","journal-title":"Nat Rev Neurol"},{"key":"6853_CR18","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barr\u00e9 syndrome. Lancet 397:1214\u20131228","journal-title":"Lancet"},{"key":"6853_CR19","doi-asserted-by":"publisher","first-page":"a028928","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD (2018) Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 8:a028928","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6853_CR20","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","volume":"48","author":"T Athar","year":"2021","unstructured":"Athar T, Al Balushi K, Khan SA (2021) Recent advances on drug development and emerging therapeutic agents for Alzheimer\u2019s disease. Mol Biol Rep 48:5629\u20135645","journal-title":"Mol Biol Rep"},{"key":"6853_CR21","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1152\/physrev.00015.2020","volume":"101","author":"C Ferrari","year":"2021","unstructured":"Ferrari C, Sorbi S (2021) The complexity of Alzheimer\u2019s disease: an evolving puzzle. Physiol Rev 101:1047\u20131081","journal-title":"Physiol Rev"},{"key":"6853_CR22","doi-asserted-by":"publisher","first-page":"755875","DOI":"10.3389\/fncel.2021.755875","volume":"15","author":"K Bohmwald","year":"2021","unstructured":"Bohmwald K, Andrade CA, G\u00e1lvez NMS, Mora VP, Mu\u00f1oz JT, Kalergis AM (2021) The causes and long-term consequences of viral encephalitis. Front Cell Neurosci 15:755875","journal-title":"Front Cell Neurosci"},{"key":"6853_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M et al (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 92:757\u2013768","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6853_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1148\/rg.2018170141","volume":"38","author":"BG Dutra","year":"2018","unstructured":"Dutra BG, da Rocha AJ, Nunes RH, Maia ACMJ (2018) Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis. Radiographics 38:169\u2013193","journal-title":"Radiographics"},{"key":"6853_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815","journal-title":"Lancet Neurol"},{"key":"6853_CR26","doi-asserted-by":"publisher","first-page":"102652","DOI":"10.1016\/j.msard.2020.102652","volume":"47","author":"SC Ibis","year":"2021","unstructured":"Ibis SC, Omaira M, Arnoldo S, Elizabeth A, Sandra M, Carlota CM et al (2021) Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study. Mult Scler Relat Disord 47:102652","journal-title":"Mult Scler Relat Disord"},{"key":"6853_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/acn3.51053","volume":"7","author":"J Tani","year":"2020","unstructured":"Tani J, Liao HT, Hsu HC, Chen LF, Chang TS, Shin-Yi Lin C et al (2020) Immune-mediated axonal dysfunction in seropositive and seronegative primary Sj\u00f6gren\u2019s syndrome. Ann Clin Transl Neurol 7:819\u2013828","journal-title":"Ann Clin Transl Neurol"},{"key":"6853_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jneuroim.2015.02.014","volume":"281","author":"H Li","year":"2015","unstructured":"Li H, Dai Y, Wu AM, Sun X, Lin Y, Lv K et al (2015) Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. J Neuroimmunol 281:38\u201343","journal-title":"J Neuroimmunol"},{"key":"6853_CR29","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1007\/s10067-021-05781-w","volume":"40","author":"K Habe","year":"2021","unstructured":"Habe K, Wada H, Mizutani K, Matsushima Y, Kondo M, Yamanaka K (2021) The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease. Clin Rheumatol 40:4675\u20134683","journal-title":"Clin Rheumatol"},{"key":"6853_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa2105872","volume":"385","author":"P Verhamme","year":"2021","unstructured":"Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, B\u00fcller HR et al (2021) Abelacimab for prevention of venous thromboembolism. N Engl J Med 385:609\u2013617","journal-title":"N Engl J Med"},{"key":"6853_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fped.2018.00142","volume":"6","author":"BR Branchford","year":"2018","unstructured":"Branchford BR, Carpenter SL (2018) The role of inflammation in venous thromboembolism. Front Pediatr 6:142","journal-title":"Front Pediatr"},{"key":"6853_CR32","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3389\/fneur.2019.01230","volume":"10","author":"K Wu","year":"2019","unstructured":"Wu K, Wen L, Duan R, Li Y, Yao Y, Jing L et al (2019) Triglyceride level is an independent risk factor in first-attacked neuromyelitis optica spectrum disorders patients. Front Neurol 10:1230","journal-title":"Front Neurol"},{"key":"6853_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1476-511X-13-48","volume":"13","author":"N Sasabe","year":"2014","unstructured":"Sasabe N, Keyamura Y, Obama T, Inoue N, Masuko Y, Igarashi Y et al (2014) Time course-changes in phosphatidylcholine profile during oxidative modification of low-density lipoprotein. Lipids Health Dis 13:48","journal-title":"Lipids Health Dis"},{"key":"6853_CR34","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3390\/biomedicines9060655","volume":"9","author":"H Itabe","year":"2021","unstructured":"Itabe H, Sawada N, Makiyama T, Obama T (2021) Structure and dynamics of oxidized lipoproteins in vivo: roles of high-density lipoprotein. Biomedicines 9:655","journal-title":"Biomedicines"},{"key":"6853_CR35","doi-asserted-by":"publisher","first-page":"774418","DOI":"10.3389\/fcvm.2021.774418","volume":"8","author":"JJ Lee","year":"2021","unstructured":"Lee JJ, Chi G, Fitzgerald C, Kazmi SHA, Kalayci A, Korjian S et al (2021) Cholesterol efflux capacity and its association with adverse cardiovascular events: a systematic review and meta-analysis. Front Cardiovasc Med 8:774418","journal-title":"Front Cardiovasc Med"},{"key":"6853_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA (2021) B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol 17:399\u2013414","journal-title":"Nat Rev Neurol"},{"key":"6853_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/1735-1995.200275","volume":"22","author":"M Etemadifar","year":"2017","unstructured":"Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M et al (2017) Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 22:18","journal-title":"J Res Med Sci"},{"key":"6853_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"R Narayan","year":"2018","unstructured":"Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M et al (2018) MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 25:66\u201372","journal-title":"Mult Scler Relat Disord"},{"key":"6853_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/ene.14128","volume":"27","author":"ZG Chen","year":"2020","unstructured":"Chen ZG, Huang J, Fan R, Weng RH, Shinohara RT, Landis JR et al (2020) Urinalysis in patients with neuromyelitis optica spectrum disorder. Eur J Neurol 27:619\u2013625","journal-title":"Eur J Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06853-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06853-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:03:23Z","timestamp":1694405003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06853-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6853"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06853-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"assertion":[{"value":"9 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committee of the Beijing Tiantan Hospital, Capital Medical University (Number: KY2019-095-03).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}